Geneoscopy

Geneoscopy

Private
St. Louis, MissouriHealthcare & Life Scienceshttps://www.geneoscopy.com

Last Round

Series C

Jan 8, 2025

Total Funding Raised

$217.33M

Company Overview

Geneoscopy is a healthcare company that specializes in diagnostics technology for digestive diseases and cancer screening services.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine

Business Model

B2B2C

Customer Profile

Services & Consulting, Government Contracts, Hardware Sales

AI Layer

Application

Keywords

colorectal cancer screeningat-home cancer testCRC screeningnoninvasive diagnosticstool RNA testadvanced adenoma detectionearly cancer detectionliquid biopsymolecular diagnosticsRNA biomarkersdiagnostic AIseRNA platformFDA-approved testgastrointestinal healthIBD diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Geneoscopy Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Geneoscopy Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CJan 8, 2025
Series BNov 16, 2021
DebtNov 16, 2021
Series AOct 2, 2019
GrantOct 23, 2017
Seed
Aug 1, 2016

Key People

Founding team and executive leadership

Andrew Barnell

Co-Founder And Chief Executive Officer

Founding Team

Amit Bhalla

Chief Financial Officer

Executive Team

Geneoscopy Investors

Notable investors and investment history

InvestorRounds
Innovatus Capital PartnersDebt, Series B
NT InvestmentsSeries C, Debt, Series B, Series A
Petrichor Healthcare Capital ManagementSeries C
Granger ManagementSeries C
Arch GrantsGrant, Seed
NT Investment GroupSeries C
Cultivation CapitalSeries B, Debt, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 31, 2026

    Operates a CAP/CLIA-certified diagnostic laboratory.

  • Feb 6, 2026

    Counterclaims filed alleging breach of contract and trade secret misappropriation.

Geneoscopy Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Geneoscopy Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Geneoscopy's valuation, stock price, and market status.

Firmographic Details

HeadquartersSt. Louis, Missouri
Employee Range64
Year Founded2015
Last FundingJan 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.